share_log

德琪醫藥-B：截至2024年2月29日止月份之股份發行人的證券變動月報表

ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

香港交易所 ·  Mar 4 03:08
Summary by Moomoo AI
德琪醫藥有限公司於2024年3月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的情況。報告顯示，公司的法定/註冊股本維持不變，上月底結存及本月底結存均為2,000,000,000股，每股面值0.0001美元，總額200,000美元。在股份期權方面，根據2019年及2020年的股權激勵計劃，公司分別註銷了1,311,600股及377,400股股份期權。經註銷後，2019年股權激勵計劃及2020年股權激勵計劃的股份期權結存分別為14,360,746股及15,781,220股。本月內沒有因行使期權而得到的資金。報告中未提及其他發行將予上市的發行人股份的權證、可換股票據、或其他協議或安排的變動。
德琪醫藥有限公司於2024年3月4日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的情況。報告顯示，公司的法定/註冊股本維持不變，上月底結存及本月底結存均為2,000,000,000股，每股面值0.0001美元，總額200,000美元。在股份期權方面，根據2019年及2020年的股權激勵計劃，公司分別註銷了1,311,600股及377,400股股份期權。經註銷後，2019年股權激勵計劃及2020年股權激勵計劃的股份期權結存分別為14,360,746股及15,781,220股。本月內沒有因行使期權而得到的資金。報告中未提及其他發行將予上市的發行人股份的權證、可換股票據、或其他協議或安排的變動。
DEKI PHARMACEUTICALS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 4 MARCH 2024, COVERING THE SITUATION AS OF 29 FEBRUARY 2024. The report shows that the company's regulated/registered share capital remained unchanged, with 2,000,000,000 shares outstanding at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share for a total of $200,000. In terms of stock options, under the Equity Incentive Scheme for 2019 and 2020, the Company has written off 1,311,600 shares and 377,400 share options, respectively. After the write-off, 14,360,746 shares and 15,781,220 shares were deposited in the stock options for the 2019 Equity Incentive Plan and the 2020 Stock Incentive Plan. No funds received during the month due to exercise options. The report does not mention changes in other issuance of warrants, convertible notes, or other agreements or arrangements for issuer shares to be issued to the public.
DEKI PHARMACEUTICALS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 4 MARCH 2024, COVERING THE SITUATION AS OF 29 FEBRUARY 2024. The report shows that the company's regulated/registered share capital remained unchanged, with 2,000,000,000 shares outstanding at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share for a total of $200,000. In terms of stock options, under the Equity Incentive Scheme for 2019 and 2020, the Company has written off 1,311,600 shares and 377,400 share options, respectively. After the write-off, 14,360,746 shares and 15,781,220 shares were deposited in the stock options for the 2019 Equity Incentive Plan and the 2020 Stock Incentive Plan. No funds received during the month due to exercise options. The report does not mention changes in other issuance of warrants, convertible notes, or other agreements or arrangements for issuer shares to be issued to the public.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more